Federal award (DEFINITIVE CONTRACT, fiscal year 2021)
Recipient: CELL MICROSYSTEMS INC
Awarding agency: Department of Health and Human Services / National Institutes of Health
Funding agency: Department of Health and Human Services / National Institutes of Health
Period of performance: 2020-08-13 to 2023-04-12
Current total value of award: $1648645
Description: THE THE PURPOSE OF THE PHASE II PROGRAM IS TO FOCUS ON DEVELOPING A T-CELL ACTIVATION PROTOCOL CONSISTENT WITH REPORTERCELL VIABILITY, DEVELOPING A PROPRIETARY REPORTER CELL LINE AND GATHERING AND BENCHMARKING PATIENT DERIVED SAMPLES WITHTHE QVOA MET